Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study.

Saved in:
Bibliographic Details
Title: Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study.
Authors: Pandiri M; Pathology (Hematopathology & Cancer Cytogenetics), Medicine (Hematology/Oncology), The University of Chicago Medicine, Chicago, Illinois, USA girish.venkataraman@uchospitals.edu madhavi.pandiri@uchicagomedicine.org., Stengel A; MLL - Munich Leukemia Laboratory, Munich, Germany., Zhang J; Pathology (Hematopathology & Children's Hospital of Colorado), UC Health University of Colorado Hospital, Anschutz Medical Campus, Aurora, Colorado, USA., Wang P; Pathology (Hematopathology & Cancer Cytogenetics), Medicine (Hematology/Oncology), The University of Chicago Medicine, Chicago, Illinois, USA., Shao H; Pathology (Hematopathology), Medicine (Hematology Oncology), H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Velmurugan S; Pathology (Hematopathology & Cancer Cytogenetics), Medicine (Hematology/Oncology), The University of Chicago Medicine, Chicago, Illinois, USA., Jacob A; Pathology (Hematopathology & Cancer Cytogenetics), Medicine (Hematology/Oncology), The University of Chicago Medicine, Chicago, Illinois, USA., Symes E; Pathology (Hematopathology & Cancer Cytogenetics), Medicine (Hematology/Oncology), The University of Chicago Medicine, Chicago, Illinois, USA., Kaur A; Pathology (Molecular Pathology), Endeavor Health Northshore Hospital, Evanston, Illinois, USA., Rojek A; Pathology (Hematopathology & Cancer Cytogenetics), Medicine (Hematology/Oncology), The University of Chicago Medicine, Chicago, Illinois, USA., Sojitra P; Pathology, Rutgers, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA., Wiredja D; Pathology (Hematopathology & Children's Hospital of Colorado), UC Health University of Colorado Hospital, Anschutz Medical Campus, Aurora, Colorado, USA., Zhou Q; Laboratory Medicine and Pathobiology (Hematopathology), Laboratory Hematology (Laboratory Medicine Program), University of Toronto, Toronto, Ontario, Canada., Chang H; Laboratory Medicine and Pathobiology (Hematopathology), Laboratory Hematology (Laboratory Medicine Program), University of Toronto, Toronto, Ontario, Canada., Patil E; Pathology (Hematopathology & Cancer Cytogenetics), Medicine (Hematology/Oncology), The University of Chicago Medicine, Chicago, Illinois, USA., Patel JL; Pathology (Hematopathology), Internal Medicine (Hematology and Hematological Malignancies), The University of Utah School of Medicine, Salt Lake City, Utah, USA., Patel AB; Pathology (Hematopathology), Internal Medicine (Hematology and Hematological Malignancies), The University of Utah School of Medicine, Salt Lake City, Utah, USA., Menon M; Pathology (Hematopathology), Internal Medicine (Hematology and Hematological Malignancies), The University of Utah School of Medicine, Salt Lake City, Utah, USA., Ghosh S; Pathology (Hematopathology), Henry Ford Health System, Detroit, Michigan, USA., Wool GD; Pathology (Hematopathology & Cancer Cytogenetics), Medicine (Hematology/Oncology), The University of Chicago Medicine, Chicago, Illinois, USA., Arber DA; Pathology (Hematopathology & Cancer Cytogenetics), Medicine (Hematology/Oncology), The University of Chicago Medicine, Chicago, Illinois, USA., Pan Z; Pathology (Hematopathology & Children's Hospital of Colorado), UC Health University of Colorado Hospital, Anschutz Medical Campus, Aurora, Colorado, USA., Findley A; Medicine (Internal Medicine & Hematology- Oncology), Mayo Clinic, Jacksonville, Florida, USA., Badar T; Medicine (Internal Medicine & Hematology- Oncology), Mayo Clinic, Jacksonville, Florida, USA., Tariq H; Pathology (Hematopathology), Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Sallman D; Pathology (Hematopathology), Medicine (Hematology Oncology), H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Bell RC; Pathology (Division of Genomic Pathology & Hematopathology), University of Michigan, Ann Arbor, Michigan, USA., Perry A; Pathology (Division of Genomic Pathology & Hematopathology), University of Michigan, Ann Arbor, Michigan, USA., Haferlach C; MLL - Munich Leukemia Laboratory, Munich, Germany., Fitzpatrick C; Pathology (Hematopathology & Cancer Cytogenetics), Medicine (Hematology/Oncology), The University of Chicago Medicine, Chicago, Illinois, USA., Venkataraman G; Pathology (Hematopathology & Cancer Cytogenetics), Medicine (Hematology/Oncology), The University of Chicago Medicine, Chicago, Illinois, USA girish.venkataraman@uchospitals.edu madhavi.pandiri@uchicagomedicine.org.
Source: Journal of clinical pathology [J Clin Pathol] 2025 Aug 18; Vol. 78 (9), pp. 629-635. Date of Electronic Publication: 2025 Aug 18.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: BMJ Pub. Group Country of Publication: England NLM ID: 0376601 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-4146 (Electronic) Linking ISSN: 00219746 NLM ISO Abbreviation: J Clin Pathol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1472-4146
DOI:10.1136/jcp-2024-209954